As previously reported, DA Davidson upgraded Procter & Gamble to Buy from Neutral with a price target of $209, up from $160. After P&G said 11/11 sales in China were as expected and that SK-II’s China sales have been up year-over-year since September’s LXP launch, the firm now has greater confidence that P&G’s organic sales can accelerate to 4%-6% in the second half of FY25, the analyst tells investors, noting that the firm is raising its FY25 organic sales growth forecast to 3.5% from 3.0% and its EPS view by 5c to $7.03.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PG:
- Procter & Gamble upgraded to Buy from Neutral at DA Davidson
- Procter & Gamble price target raised to $167 from $165 at Stifel
- Procter & Gamble sees long-term core EPS growth in mid-to-high single digits
- Procter & Gamble reiterates FY25 organic revenue growth view of 3%-5%
- Eli Lilly appoints Jon Moeller to board of directors